GlassScriptPhysician profile
Steven P Thompson
NPI 1659551851
$4,932.58
in general payments reported to CMS, 2019-2025
24 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $860 · 2022: $789 · 2023: $479 · 2024: $1,193 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,712.18 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $678.87 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Madrigal Pharmaceuticals | $377.85 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $237.37 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $191.71 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $169.71 | 2021-2024 | Dificid |
| Novo Nordisk INC | $167.48 | 2025 | Wegovy |
| Janssen Biotech, INC. | $161.86 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $159.60 | 2024-2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $152.12 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $148.65 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $140.92 | 2022-2024 | Linzess |
| Ardelyx, INC. | $140.49 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $130.40 | 2021-2022 | |
| Evoke Pharma, INC. | $75.22 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $61.66 | 2023-2024 | Accrufer |
| Gilead Sciences, INC. | $45.65 | 2023-2024 | Epclusa |
| Braintree Laboratories, INC. | $39.90 | 2022-2025 | Suflave, Sutab |
| Exact Sciences Corporation | $34.57 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $30.94 | 2023 | |
| Genzyme Corporation | $25.01 | 2024 | |
| Amgen INC. | $21.13 | 2025 | Uplizna |
| Alnylam Pharmaceuticals INC. | $14.84 | 2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.45 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.